Skip to main content
RYVU Therapeutics S.A. logo

RYVU Therapeutics S.A. — Investor Relations & Filings

Ticker · RVU ISIN · PLSELVT00013 LEI · 2594003WO9Q9HHAFL031 WAR Professional, scientific and technical activities
Open in API
Filings indexed 811 across all filing types
Latest filing 2026-03-19 Audit Report / Informat…
Country PL Poland
Listing WAR RVU

About RYVU Therapeutics S.A.

https://ryvu.com/

Ryvu Therapeutics is a clinical-stage drug discovery and development company specializing in novel small molecule therapies for oncology. The company's research focuses on emerging biological targets and pathways, including kinase inhibition, synthetic lethality, and immuno-oncology, to develop precise cancer treatments. Its pipeline features several candidates in various stages of development. Key clinical-stage assets include Romaciclib (RVU120), a selective CDK8/19 kinase inhibitor for treating hematologic malignancies like acute myeloid leukemia (AML) and myelofibrosis, and Dapolsertib (MEN1703), a PIM/FLT3 inhibitor. The company also advances preclinical programs, such as an MTA-cooperative PRMT5 inhibitor for solid tumors with MTAP deletion.

Recent filings

Filing Released Lang Actions
Sprawozdanie biegłego rewidenta z badania 2025 ENG
Audit Report / Information Classification · 100% confidence The document is a 'Sprawozdanie niezależnego biegłego rewidenta z badania' (Independent Auditor's Report) for Ryvu Therapeutics S.A. It details the audit procedures, key audit matters (revenue, grants, EIB financing), and the auditor's opinion on the financial statements for the year ended December 31, 2025. As it is a standalone audit report and not the full annual report itself, it falls under the Audit Report category. FY 2025
2026-03-19 Polish
Sprawozdanie biegłego rewidenta z badania 2025 PL
Audit Report / Information Classification · 100% confidence The document is an 'Independent Auditor's Report' issued by Ernst & Young for Ryvu Therapeutics S.A. It details the audit opinion on the company's annual financial statements for the period ending December 31, 2025, including key audit matters such as sales revenue, grant income, and financing from the European Investment Bank. As this is a standalone audit report and not the full annual report (10-K) or a management report, it falls under the Audit Report category. FY 2025
2026-03-19 English
Oświadczenie RN ws. Sprawozdania Finanowego oraz Sprawozdania Zarządu PL / ENG
Audit Report / Information Classification · 95% confidence The document is a formal assessment by the Supervisory Board of Ryvu Therapeutics S.A. regarding the company's annual management report and financial statements for the year 2025. It is a standalone report detailing the board's oversight and audit-related evaluation of the company's financial reporting, which falls under the category of Audit Report / Information (AR). FY 2025
2026-03-19 Polish
Oświadczenie RN ws. funkcjonowania Komiretu audytu oraz Audytora 2025 PL / ENG
Audit Report / Information Classification · 95% confidence The document is a formal statement from the Supervisory Board of Ryvu Therapeutics S.A. regarding the functioning of the Audit Committee and the independence of the external auditor (Ernst & Young). It cites specific regulatory requirements (Regulation of the Minister of Finance) related to the publication of the annual report. This type of document, which confirms compliance with audit-related governance standards, falls under the category of Audit Report / Information (AR) as it pertains to the audit process and auditor independence rather than being the financial report itself or a general governance report. FY 2025
2026-03-19 Polish
List Prezesa Ryvu do AKcjonariuszy ENG
Management Reports Classification · 95% confidence The document is a letter from the CEO of Ryvu Therapeutics to investors and partners, summarizing the company's 2025 operational and clinical performance, discussing clinical trial results (romaciclib, dapolsertib), R&D progress, and outlining strategic priorities for 2026. It includes financial highlights and management commentary on business trends. This fits the definition of a Management Report (MDA), which provides management's detailed explanation of business trends, operational results, and outlook.
2026-03-19 English
List Prezesa Ryvu do Akcjonariuszy PL
Management Reports Classification · 95% confidence The document is a letter from the CEO of Ryvu Therapeutics to investors, partners, and stakeholders. It provides a comprehensive review of the company's 2025 performance, clinical trial updates (romacyklib, dapolsertib), R&D progress, financial status, and strategic priorities for 2026. It functions as a management commentary on business trends and outlook, which aligns with the definition of a Management Report (MDA).
2026-03-19 Polish

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.